The 7-OH category’sits inside a family of kratom alkaloids, and the family map is where the 2026 legal news lands: some of the family is scheduled, some is pending, and the one most buyers know by name is in between. This post is the full family comparison — what each alkaloid is, what it is used for, and where each one sits in the 2026 regulatory picture. The two posts this one builds on: the mitragynine vs 7-OH comparison (the two big ones) and the DEA 2026 update (the regulatory side). Standing rules: 21+ adult framing, no medical claims, no dosing advice — this is a chemistry-and-legal map, not a use guide.
The family map (as of September 2026)
| Alkaloid | What it is | Federal status | Where you will meet it |
|---|---|---|---|
| Mitragynine | The primary native kratom alkaloid; the leaf s headline compound | Not scheduled | Kratom leaf and lower-concentration products — the leaf comparison |
| 7-hydroxymitragynine (7-OH) | A native alkaloid, present in trace amounts in the leaf; the tablet category’s compound | Not scheduled — threshold rule pending (notice July 6, 2026) | The concentrated tablet/chewable category — the what is 7-OH post |
| Mitragynine pseudoindoxyl (MP) | A semi-synthetic kratom alkaloid (7-OH’s synthetic route product); circulated in research-chemical channels | Temporary Schedule I — Aug 26, 2026 | Not in a legitimate 7-OH product; the COA screens cover it |
| MGM-15 | A kratom alkaloid analog; appeared as a 7-OH’substitute after the state restrictions began | Temporary Schedule I — Aug 26, 2026 | The substitute segment — now a controlled-compound market |
| MGM-16 | The second analog in the substitute line | Temporary Schedule I — Aug 26, 2026 | The substitute segment — now a controlled-compound market |
Read the status column as the buyer s version of the map: the scheduled rows are controlled compounds (the DEA update has the actions and the dates), the pending row is the one to watch (the federal status guide tracks it), and the unscheduled rows are where the lawful product space sits — subject to the state map in the state overview.
Mitragynine: the parent compound
Mitragynine is the alkaloid the leaf is known for — the primary native compound of Mitragyna speciosa, the one that defines the plant s profile and the traditional kratom product space. Its relationship to 7-OH is the dedicated comparison s subject, and the short version for this post: the two are distinct compounds with distinct profiles, and the 7-OH category exists because 7-OH’s relative potency per milligram is the higher one — the premise the what is stronger post covers from the buyer s side. Mitragynine remains unscheduled at the federal level, which is why the leaf product space stays in the leaf comparison s lane: a different product, a different legal position, a different precision story (the powder comparison is the dosing-side version).
MP and the analogs: why the scheduled rows matter to a 7-OH buyer
The scheduled compounds are not 7-OH, and a legitimate 7-OH product does not contain them — which is exactly why they matter:
- They define the lab panel. The related-compound screens on a current batch COA exist to show the profile is clean — the 7-OH is 7-OH, and the scheduled analogs are not in it. The COA guide shows where to look, and the batch verification habit is the five-minute check. A vendor whose COA does not screen the scheduled compounds is a vendor outside the 2026 standard.
- They mark the substitute market. The analogs appeared as substitutes after the state restrictions began targeting 7-OH, and the scheduling action closed that lane: the substitutes are now controlled compounds in every state, permitted or restricted. The legal alternatives post is the honest read on what that means for a buyer looking around the restriction — the short version is that the substitutes are not the workaround, they are the next exposure.
- They show the regulators targeting the family, not the leaf. The pattern across the 2026 actions: the native leaf compound (mitragynine) is untouched, the concentrated native compound (7-OH) is pending, and the semi-synthetic and analog rows are scheduled. The concentration and the synthesis are the signals the regulators are reading — the federal status guide is the standing reference for where the next move lands.
What the comparison means for a buyer, practically
- The product question is the family question. When a vendor’s listing says 7-OH, the buyer s check is the family: is the pack s COA showing 7-hydroxymitragynine as the labeled compound, with the related-compound screens clean? The what is 7-OH post is the labeling side of the same check.
- The legal question is the status question. The state map decides the state layer (the state overview), and the federal status decides the federal layer (the federal status). The two layers are checked separately, in that order — the legal status guide is the combined read.
- The precision question is the format question. The alkaloid family is constant across formats; the precision is not. The tablets vs gummies and chewable vs tablet comparisons are the format side of the same product decision.
Bottom line
The family map, in one line: mitragynine is the native leaf compound (unscheduled), 7-OH is the concentrated native compound (pending the threshold rule), and the MP/MGM-15/MGM-16 rows are scheduled since August 26, 2026 — which is why the related-compound screens on your batch COA are the 2026 standard, and why the substitutes are a controlled-compound market, not a workaround. The mitragynine comparison is the deep read on the two main compounds, the DEA update is the regulatory record, and the FAQ center carries the standing questions. Our shop sells the 7-OH lane of the family — verified units, batch COAs, 21+ only, legal addresses only.